| Variable | Placebo (n = 5) | Adalimumab 40 mg eow (n = 6) |
| Male, n (%) | 5 (100) | 4 (66.7) |
| White, n (%) | 5 (100) | 6 (100) |
| Age (years), mean (SD) | 50.2 (7.8) | 54.2 (5.9) |
| Disease duration (years), mean (SD) | 16.6 (5.9) | 25.6 (7.4) |
| HLA-B27 positive, n (%) | 5 (100) | 4 (66.7) |
| DMARD use prior to or at baseline, n (%) | 5 (100) | 4 (66.7) |
| Concomitant NSAID use, n (%) | 4 (80.0) | 5 (83.3) |
| Concomitant corticosteroid use, n (%) | 0 (0) | 0 (0) |
| Patient’s global assessment of disease activity (cm), mean (SD) | 6.2 (1.9) | 8.7 (1.0) |
| Total back pain (cm), mean (SD) | 5.1 (3.4) | 6.6 (3.4) |
| Inflammation* (cm), mean (SD) | 7.8 (1.7) | 8.0 (0.8) |
| BASFI (cm), mean (SD) | 7.5 (1.3) | 8.0 (1.1) |
| BA(SD)AI (cm), mean (SD) | 6.1 (1.6) | 7.6 (1.0) |
| CRP (mg/dL), mean (SD) | 2.9 (2.9) | 3.3 (2.6) |
| BASMI (0–10), mean (SD) | 6.4 (1.3) | 7.8 (0.8) |
BA(SD)AI, Bath Ankylosing Spondylitis Disease Activity Index; BASFI, Bath Ankylosing Spondylitis Functional Index; BASMI, Bath Ankylosing Spondylitis Metrology Index; CRP, C-reactive protein; DMARD, disease-modifying anti-rheumatic drug; eow, every other week; NSAID, non-steroidal anti-inflammatory drug.
*Mean of questions 5 and 6 of the BA(SD)AI.